New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2013
11:18 EDTSHLD, QCOR, MNST, SPLK, BYDOptions with decreasing implied volatility: QCOR BYD MNST SHLD SPLK
News For QCOR;BYD;MNST;SHLD;SPLK From The Last 14 Days
Check below for free stories on QCOR;BYD;MNST;SHLD;SPLK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 8, 2014
05:31 EDTQCORQuestcor downgraded to Hold from Buy at Jefferies
Jefferies downgraded Questcor (QCOR) to Hold with an $86 price target following the company's merger agreement with Mallinckrodt (MNK).
April 7, 2014
16:28 EDTQCOROn The Fly: Closing Wrap
Subscribe for More Information
12:15 EDTQCOROn The Fly: Midday Wrap
Subscribe for More Information
11:21 EDTQCOROptions with decreasing implied volatility: QCOR MU KMX EPB
11:05 EDTQCOR High option volume stocks: EXC QCOR SQQQ GNK PPG
Subscribe for More Information
10:40 EDTQCORShort-seller target Questcor spikes after deal to be bought by Mallinckrodt
Questcor (QCOR) shares are sharply higher this morning after the company agreed to be bought by Mallinckrodt (MNK) in a transaction valued at approximately $5.6B. WHAT'S NEW: Questcor, a biopharmaceutical company whose primary drug, H.P. Acthar Gel, is approved by the FDA for the treatment of 19 indications, will be acquired by Mallinckrodt for about $5.6B, made up of $30.00 per share in cash and 0.897 Mallinckrodt shares for each Questcor share they own. The total consideration equated to approximately $86.10 per Questcor share based on the closing price of Mallinckrodt shares on April 4. After the deal closes, Mallinckrodt shareholders will own approximately 50.5% and former Questcor shareholders will own approximately 49.5% of the combined company's stock. The deal is expected to immediately add to Mallinckrodt's fiscal 2014 adjusted earnings per share and significantly add to fiscal 2015 adjusted EPS. The transaction is targeted to close in the third quarter. On the companies' conference call discussing the merger, Questcor said it believes that its first quarter sales will be "somewhat lower" than the fourth quarter of 2013, but also "substantially higher" than last year's first quarter; the consensus estimate for Q1 revenue is $242.08M. Questcor also said that it sees a "favorable" tax structure and operating cash flow, as well as immediate value for shareholders. Mallinckrodt said sees about a 10% decline in the tax rate with the Questcor deal and believes it will realize immediate tax benefits. Mallinckrodt added that its focus will be on deleveraging in the coming months to allow for strategic acquisitions. WHAT'S NOTABLE: Of the 19 indications approved for Acthar, Questcor currently generates substantially all of its net sales from the following on-label indications: the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions. Questcor has been a frequent target of the short-selling blog Citron Research in the past. As recently as March 14, Citron Research claimed Questcor was "deceiving" the FDA and investors, alleging H.P. Acthar Gel's active ingredient is less than 20% of the label specification. PRICE ACTION: Questcor is trading up $11.48, or 16.91%, to $79.35 in mid-morning trading. Meanwhile, Mallinckrodt is down $1.70, or 2.72%, to $60.82.
10:10 EDTSPLKAnalyst sees 'golden' opportunity after software stocks decline
Subscribe for More Information
10:00 EDTQCORQuestcor rises 21.2%
Subscribe for More Information
09:10 EDTQCOROn The Fly: Pre-market Movers
HIGHER: Questcor (QCOR), up 27% after agreeing to be bought by Mallinckrodt (MNK) for cash, stock valued at $86.10 per Questcor share... Agios Pharmaceuticals (AGIO), up 25% after program shows "promising clinical activity" for advanced blood cancers, shares upgraded at JPMorgan... Vocus (VOCS), up 47% after agreeing to be acquired by GTCR for $446.5M, or $18.00 per share... Pandora (P), up 1.3% following upgrade at Wedbush. LOWER: MannKind (MNKD), down 13% after announcing FDA extension of PDUFA date for Afrezza... American Eagle (AEO), down 2.2% following downgrade at Cowen... Pfizer (PFE), down 2.8% after announcing data for palbociclib in metastatic breast cancer... Mattel (MAT), down 3% following downgrade at BMO Capital... WWE (WWE), down 1.2% after cautious mention in Barron's, company announcing WrestleMania 30 grossed $10.9M.
09:00 EDTQCORQuestcor rises 29.2%
Subscribe for More Information
08:49 EDTSPLKFBR sees 'golden buying opportunity' in enterprise software
FBR Capital says a "'golden buying opportunity" exists in the enterprise software space following the recent sell-off of high-growth names. The firm believes overall software results in Q1 tracked in line to slightly ahead of expectations. It recommends buying Splunk (SPLK), Salesforce.com (CRM), Workday (WDAY), FireEye (FEYE), NetSuite (N) and Palo Alto (PANW) on the recent pullbacks.
07:16 EDTQCORMallinckrodt and Questcor hold a joint conference call
Subscribe for More Information
07:08 EDTQCORQuestcor to be bought by Mallinckrodt for cash, stock valued at $86.10 per share
Subscribe for More Information
07:04 EDTQCORQuestcor acquired by Mallinckrodt for $5.6B
Subscribe for More Information
07:01 EDTSHLDEquity One names David Lukes as next CEO
Subscribe for More Information
April 5, 2014
19:03 EDTSHLDSears completes Land's End spin-off, receives $500M in gross proceeds
Sears Holdings (SHLD) announced that its pro-rata spin-off of Lands' End (LE) from Sears Holdings closed on April 4. Lands' End has now been separated from Sears Holdings and its common stock is expected to begin regular-way trading on the Nasdaq Capital Market under the symbol LE on April 7. Sears Holdings will continue to be listed on the Nasdaq Global Select Market under the symbol SHLD. Sears Holdings received aggregate gross proceeds from the spin-off of $500M, consisting of a cash dividend paid by Lands' End prior to the spin-off to a subsidiary of Sears Holdings. In the spin-off, Sears Holdings distributed a total of approximately 32M shares of Lands' End common stock to the holders of Sears Holdings common stock as of 5:30 p.m. Eastern time on March 24, the record date. Each share of Sears Holdings common stock outstanding as of the record date entitles the holder thereof to receive 0.300795 shares of Lands' End common stock, except that holders of Sears Holdings' restricted stock that was unvested as of the record date will receive cash awards in lieu of shares. In addition, as part of the spin-off, Lands' End entered into an asset-based senior secured revolving credit facility, which provides for maximum borrowings of approximately $175M with a letter of credit sub-limit, and a senior secured term loan facility of approximately $515M. The proceeds of the term loan facility were used to pay the $500M dividend to the Sears Holdings subsidiary and to pay fees and expenses associated with the foregoing facilities of approximately $10M, with the remaining proceeds to be used by Lands' End for general corporate purposes.
April 4, 2014
10:04 EDTSHLDSears risk/reward negative, says ISI Group
Subscribe for More Information
April 3, 2014
12:42 EDTMNSTEnergy drink MLM changes practices amid scrutiny of Herbalife, NY Post says
Vemma, a multilevel marketing company that makes Verve brand energy drinks, said it is changing its business practices as the Federal Trade Commission investigates Herbalife (HLF), which has a similar business model, reported The New York Post. Monster Beverage (MNST), which like Herbalife has drawn a fair amount of scrutiny from lawmakers, markets energy drinks that compete with Vemma's. Reference Link
10:00 EDTSPLKOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:59 EDTSPLK, SPLKSplunk upgraded to Outperform from Underperform at CLSA
CLSA upgraded Splunk due to valuation. Price target is $80.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use